Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYML-122 plus cytarabine in FLT3-mutated relapsed or refractory acute myeloid leukemia
CTR20211957Phase 2Active
- Sponsor
- Hefei Cosource Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CHMFL-FLT3-122, cytarabine in acute myeloid leukemia (AML), sponsored by Hefei Cosource Pharmaceutical. Started Apr 2022; status: active.
02
Drugs
CHMFL-FLT3-122cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20211957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211957.